Lymph Node Metastasis after a Soft Tissue Sarcoma of the Leg: A Case Report and a Review of the Literature

Table 1

Four studies on the number of patients with a STS who develop RLNM.

Type of tumor	Number of patients	Number of RLNMs	Percentage
Synovial sarcoma
Mazeron and Suit [9]	15	0	0%
Review Mazeron and Suit [9]	851	117	14%
Fong et al. [10]	145	2	1%
Daigeler et al. [11]	111	4	4%
Behranwala et al. [12]	171	7	4%
Total	1293	130	10%
Fibrosarcoma
Mazeron and Suit [9]	45	0	0%
Review Mazeron and Suit [9]	215	54	25%
Fong et al. [10]	162	0	0%
Daigeler et al. [11]	45	1	2%
Behranwala et al. [12]	132	1	1%
Total	599	56	9%
Malignant fibrohistiocytoma
Mazeron and Suit [9]	48	1	2%
Review Mazeron and Suit [9]	823	84	10%
Fong et al. [10]	316	8	3%
Behranwala et al. [12]	235	3	1%
Total	1422	96	7%
Neurofibrosarcoma
Mazeron and Suit [9]	20	1	5%
Review Mazeron and Suit [9]	476	3	1%
Fong et al. [10]	96	2	2%
Daigeler et al. [11]	94	3	3%
Behranwala et al. [12]	95	4	4%
Total	781	13	2%
Liposarcoma
Mazeron and Suit [9]	55	2	4%
Review Mazeron and Suit [9]	504	16	3%
Fong et al. [10]	403	3	1%
Daigeler et al. [11]	333	1	0%
Behranwala et al. [12]	340	3	1%
Total	1635	25	2%
Rhabdomyosarcoma
Mazeron and Suit [9]	15	5	33%
Review Mazeron and Suit [9]	1354	201	15%
Fong et al. [10]	123	13	11%
Daigeler et al. [11]	50	3	6%
Behranwala et al. [12]	54	12	22%
Total	1596	234	15%
Leiomyosarcoma
Mazeron and Suit [9]	30	1	3%
Review Mazeron and Suit [9]	524	21	4%
Fong et al. [10]	328	9	3%
Daigeler et al. [11]	167	1	1%
Behranwala et al. [12]	483	13	3%
Total	1532	45	3%
Vascular sarcoma
Mazeron and Suit [9]	14	2	14%
Fong et al. [10]	37	5	14%
Daigeler et al. [11]	38	3	8%
Behranwala et al. [12]	46	5	11%
Total	135	15	11%
Epithelioid sarcoma
Mazeron and Suit [9]	7	5	71%
Review Mazeron and Suit [9]	70	14	20%
Fong et al. [10]	12	2	17%
Daigeler et al. [11]	28	6	21%
Behranwala et al. [12]	27	5	19%
Total	144	32	22%
Clear cell
Review Mazeron and Suit [9]	40	11	28%
Daigeler et al. [11]	14	3	21%
Behranwala et al. [12]	25	1	4%
Total	79	15	19%
NOS
Mazeron and Suit [9]	42	2	5%
Fong et al. [10]	27	0	0%
Daigeler et al. [11]	268	2	1%
Behranwala et al. [12]	10	1	10%
Total	347	5	1%
Dermatofibrosarcoma Protuberans
Daigeler et al. [11]	48	1	2%
Behranwala et al. [12]	43	1	2%
Total	91	2	2%